Patent: 10,344,029
✉ Email this page to a colleague
Summary for Patent: 10,344,029
| Title: | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof |
| Abstract: | The present disclosure provides compounds of structural Formula III: ##STR00001## or a salt thereof, wherein Y is chosen from ##STR00002## Further provided are pharmaceutical compositions comprising these compounds, and methods for treating cancer, such as pancreatic cancer or synovial sarcoma, using the compounds and compositions. |
| Inventor(s): | Hawkins; William (St. Louis, MO), Mach; Robert (St. Louis, MO), Spitzer; Dirk (St. Louis, MO), Vangveravong; Suwanna (St. Louis, MO), Van Tine; Brian (St. Louis, MO) |
| Assignee: | Washington University (St. Louis, MO) |
| Application Number: | 16/111,842 |
| Patent Claims: | see list of patent claims |
Details for Patent 10,344,029
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2034-04-01 |
| Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 02/20/1991 | ⤷ Try a Trial | 2034-04-01 |
| Amgen, Inc. | NEUPOGEN | filgrastim | Injection | 103353 | 06/28/2000 | ⤷ Try a Trial | 2034-04-01 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
